Product Description
Mechanisms of Action: CAR-T,ERBB2
Novel Mechanism: Yes
Modality: CAR-T
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sironax
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ACTRN12624000562572 | P1 |
Recruiting |
Healthy Volunteers |
2025-04-15 |
2025-06-02 |
Treatments |
|
| ACTRN12624001334594 | P1 |
Recruiting |
Healthy Volunteers |
2025-10-15 |
2025-06-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/10/2023 |
PubMed |
Epitaxial Growth of High-Quality Monolayer MoS(2) Single Crystals on Low-Symmetry Vicinal Au(101) Facets with Different Miller Indices. |
|
06/10/2021 |
News Article |
CAR T Cell Therapy Pipeline Insight Report 2021 - ResearchAndMarkets.com |
|
02/17/2021 |
PubMed |
'Puppy Dog Eyes' Are Associated With Eye Movements, Not Communication. |
|
11/03/2020 |
PubMed |
Equine Facial Action Coding System for determination of pain-related facial responses in videos of horses. |